Bavituximab
drugOn this page
Also known as CH3G4TARVACIN
Summary
Bavituximab (CHEMBL1742989) is a phase-3 clinical-stage antibody; indicated across 16 conditions including non-small cell lung carcinoma and exocrine pancreatic carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 16 conditions
- Clinical trials: 23
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1742989 |
| Name | Bavituximab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Bavituximab, CH3G4, TARVACIN, BAVITUXIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
16 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| carcinoma | 2 | MONDO:0004993 | EFO:0000313 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| triple-negative breast carcinoma | 2 | MONDO:0005494 | EFO:0005537 |
| squamous cell carcinoma | 2 | MONDO:0005096 | EFO:0000707 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| hepatitis C virus infection | 1 | MONDO:0005231 | EFO:0003047 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| prostate adenocarcinoma | 1 | MONDO:0005082 | EFO:0000673 |
| melanoma | 1 | MONDO:0005105 | EFO:0000756 |
| male breast carcinoma | 1 | MONDO:0005628 | EFO:0006861 |
| rectal cancer | 1 | MONDO:0006519 | EFO:1000657 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 23.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 11 |
| PHASE1 | 8 |
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01999673 | PHASE3 | COMPLETED | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer |
| NCT02651610 | PHASE2/PHASE3 | WITHDRAWN | Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer |
| NCT03519997 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma |
| NCT04150900 | PHASE2 | ACTIVE_NOT_RECRUITING | 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck |
| NCT00669565 | PHASE2 | COMPLETED | Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer |
| NCT00669591 | PHASE2 | COMPLETED | A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer |
| NCT01160601 | PHASE2 | COMPLETED | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer |
| NCT01264705 | PHASE1/PHASE2 | COMPLETED | Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer |
| NCT01272791 | PHASE2 | COMPLETED | Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer |
| NCT01273948 | PHASE1/PHASE2 | COMPLETED | Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection |
| NCT02673814 | PHASE2 | WITHDRAWN | Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer |
| NCT02685306 | PHASE2 | WITHDRAWN | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer |
| NCT03139916 | PHASE2 | COMPLETED | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma |
| NCT04099641 | PHASE2 | COMPLETED | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients |
| NCT05249569 | PHASE2 | TERMINATED | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma |
| NCT00128271 | PHASE1 | COMPLETED | Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection |
| NCT00129337 | PHASE1 | COMPLETED | Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies |
| NCT00343525 | PHASE1 | COMPLETED | Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C |
| NCT00503347 | PHASE1 | COMPLETED | Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus |
| NCT01288261 | PHASE1 | COMPLETED | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer |
| NCT01323062 | PHASE1 | COMPLETED | Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects |
| NCT01634685 | PHASE1 | COMPLETED | A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma |
| NCT02989870 | PHASE1 | WITHDRAWN | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: non-small cell lung carcinoma